Alluvi, previously BI 4744, presents a notable advance in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable effectiveness in clinical https://alluvi-peptides860517.my21blog.com/profile